In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device/Diagnostics Quarterly Deal-Making Statistics, Q2 2017

A look at financing, M&A and alliance activity April–June 2017

Executive Summary

Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.

Advertisement

Related Content

Spectranetics Gives Philips Adjacent Territory In Image-Guided Therapy
Philips Puts Its Money On Electrical Geodesics – The Universal Brain Flashlight
Philips Targets Bolt-On Deals That Meet Demand At The Point Of Care
PerkinElmer Solidifies OUS Presence With $1.3bn EUROIMMUN Buy
New Acquisition And Positive Data Inflates Philips' Respiratory Biz
BD, CR Bard Merger To Create Vascular Access Device Giant
Cardinal Health, Medtronic Tie Up $6.1bn Lower-Margin Assets Deal
BioTelemetry Trumps Aevis' Takeover Bid For LifeWatch
Endologix Lifts Hold On Shipments Of AAA Devices

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV005190

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel